A controversial decision
EFSA said it wanted to make an effort to engage in "an open dialogue with stakeholders" through a briefing. The EU agency then sought to clarify the reasoning behind its decision last month, having cut off dozens of applications for CBD products.
Indeed, although a panel of experts from EFSA and the European Commission responded directly to many of the CBD industry's questions, no concrete information was provided on two key issues: the likely duration of the testing process and the design of the human trials.
The Food Standards Agency (FSA), having made its final public list of CBD products official a few days after the speech, set an example for its European counterpart to follow, pointing to the poor quality of its claims and explaining that this could be one of the main reasons for a possible long delay in regulating the sector.
The reasons for this decision
According to Professor McArdle, the decision to suspend claims indefinitely became clear after extensive research into what is considered the current scientific literature. The latter consists of a large number of toxicological studies conducted on both animals and humans, generally with a wide variety of mixtures of cannabidiol and other cannabinoids.
The fact that the content and identity of these compounds are rarely well detailed to understand their contribution or the need to understand exactly how these chemicals interact with the human body has become a major issue. In addition, studies that have focused on the effects of pure CBD in humans have been confounded by the fact that patients were also taking other drugs alongside it. Finally, too much important information is missing from many dossiers such as the identity of the raw material, geographical location, taxonomy, details of the production process and verification of identity according to international methodologies.